Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.65 |
| ▸ | APP | P05067 | 6/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.43 |
| ▸ | HNF4A | P41235 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19119381 | 0.99 | RXRA (0.66) | RXRAAPPAKR1C3PPARGNR1H3 | |
| SCHEMBL26053263 | 0.87 | RXRA (0.52) | RXRAAPPAKR1C3KDM4EACHE | |
| SCHEMBL6473191 | 0.87 | RXRA (0.51) | RXRAAKR1C3PPARGNR1H3KDM4E | |
| SCHEMBL6473193 | 0.87 | RXRA (0.51) | RXRAAKR1C3PPARGNR1H3KDM4E | |
| SCHEMBL6874360 | 0.86 | RXRA (0.63) | RXRAAKR1C3KDM4ECYP26A1ACHE | |
| SCHEMBL6473263 | 0.85 | RXRA (0.67) | RXRAAPPKDM4ECYP26A1CYP26B1 | |
| SCHEMBL6473269 | 0.85 | RXRA (0.67) | RXRAAPPKDM4ECYP26A1CYP26B1 | |
| SCHEMBL6878227 | 0.85 | RXRA (0.50) | RXRAAKR1C3PPARGNR1H3KDM4E | |
| SCHEMBL6472658 | 0.84 | RXRA (0.66) | RXRAAPPAKR1C3KDM4ECYP26A1 | |
| SCHEMBL6472662 | 0.84 | RXRA (0.66) | RXRAAPPAKR1C3KDM4ECYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RXRA 1/4885APP 4857/4885AKR1C3 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.